Streptococcus pneumoniae (pneumococcus) is a major cause of worldwide mortality and
morbidity, and to a large extent is vaccine-preventable. Nasopharyngeal carriage of …

Summary Three bacteria—Haemophilus influenzae, Streptococcus pneumoniae, and
Neisseria meningitidis—account for most acute bacterial meningitis. Measurement of the …

Background Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal
disease in infants, but their efficacy against pneumococcal community-acquired pneumonia …

Background Efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) was
inferred before licensure from an aggregate correlate of protection established for the seven …

Cluster Randomised Trials, Second Edition discusses the design, conduct, and analysis of
trials that randomise groups of individuals to different treatments. It explores the advantages …

SUMMARY On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein
conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer …

Background Pneumonia is estimated to cause 2 million deaths every year in children.
Streptococcus pneumoniae is the most important cause of severe pneumonia. We aimed to …

The bacterial species Streptococcus pneumoniae consists of 90 immunologically distinct
serotypes, of which some possess distinct epidemiological properties. Certain serotypes are …

The immunogenicity of polysaccharides as human vaccines was enhanced by coupling to
protein carriers. Conjugation transformed the T cell-independent polysaccharide vaccines of …

Background: Streptococcus pneumoniae is a leading and serious coinfection in adults with
human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this …